Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls

Schizophrenia Research

Volumn 143, Issue 2-3, 2013, Pages 301-306

  Zhang, Xiang Yang ^a,b,c   Chen, Da Chun ^c   Xiu, Mei Hong ^c   Yang, Fu De ^c   Tan, Yun Long ^c   He, Shuchang ^c   Kosten, Therese A ^a,b   Kosten, Thomas R ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PEKING UNIVERSITY   (China)

Author keywords

Cognition; Oxidative stress; Psychopathology; Schizophrenia

Indexed keywords

THIOREDOXIN;

ADULT; AGED; ARTICLE; ATTENTION DISTURBANCE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; DOWN REGULATION; FEMALE; HUMAN; MALE; MEMORY DISORDER; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; OXIDATIVE STRESS; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEATED BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; RESIDUAL SCHIZOPHRENIA; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIOREDOXINS;

EID: 84872414248     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.11.017     Document Type: Article

References (62)

1. Allott K., Alvarez-Jimenez M., Killackey E.J., Bendall S., McGorry P.D., Jackson H.J. Patient predictors of symptom and functional outcome following cognitive behaviour therapy or befriending in first-episode psychosis. Schizophr. Res. 2011, 132:125-130.
2. Allott K., Liu P., Proffitt T.M., Killackey E. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr. Res. 2011, 125:221-235.
3. Ames B.N. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17589-17594.
4. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003, 53:56-64.
5. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 2000, 157:549-559.
6. Bjerner J., Bormer O.P., Nustad K. The war on heterophilic antibody interference. Clin. Chem. 2005, 51:9-11.
7. Burke-Gaffney A., Callister M.E., Nakamura H. Thioredoxin: friend or foe in human disease?. Trends Pharmacol. Sci. 2005, 26:398-404.
8. Clausen A., Doctrow S., Baudry M. Prevention of cognitive deficits and brain oxidative stress with superoxide dismutase/catalase mimetics in aged mice. Neurobiol. Aging 2010, 31:425-433.
9. Condray R., Yao J.K. Cognition, dopamine and bioactive lipids in schizophrenia. Front. Biosci. (Schol Ed.) 2011, 3:298-330.
10. Corbetta M., Patel G., Shulman G.L. The reorienting system of the human brain: from environment to theory of mind. Neuron 2008, 58:306-324.
11. Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50:279-289.
12. DeForge L.E., Loyet K.M., Delarosa D., Chinn J., Zamanian F., Chuntharapai A., et al. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J. Immunol. Methods 2010, 362(1-2):70-81.
13. Dickerson F., Boronow J.J., Stallings C., Origoni A.E., Cole S.K., Yolken R.H. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res. 2004, 129:45-53.
14. Fukui K., Onodera K., Shinkai T., Suzuki S., Urano S. Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems. Ann. N. Y. Acad. Sci. 2001, 928:168-175.
15. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
16. Harvey P.D. When does cognitive decline occur in the period prior to the first episode of schizophrenia?. Psychiatry (Edgmont) 2009, 6:12-14.
17. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J. Clin. Psychiatry 2004, 65:361-372.
18. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry 2001, 6:66-73.
19. Holmgren A. Thioredoxin. Annu. Rev. Biochem. 1985, 54:237-271.
20. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 1995, 3:239-243.
21. Hu D., Serrano F., Oury T.D., Klann E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. J. Neurosci. 2006, 26:3933-3941.
22. Hughes C., Kumari V., Soni W., Das M., Binneman B., Drozd S., et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr. Res. 2003, 59:137-146.
23. Jikimoto T., Nishikubo Y., Koshiba M., Kanagawa S., Morinobu S., Morinobu A., et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol. Immunol. 2002, 38:765-772.
24. Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 2011, 10:187-198.
25. Keefe R.S., Eesley C.E., Poe M.P. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry 2005, 57:688-691.
26. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58:1-10.
27. Kishimoto C., Shioji K., Nakamura H., Nakayama Y., Yodoi J., Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn. Circ. J. 2001, 65:491-494.
28. Kolosova N.G., Shcheglova T.V., Sergeeva S.V., Loskutova L.V. Long-term antioxidant supplementation attenuates oxidative stress markers and cognitive deficits in senescent-accelerated OXYS rats. Neurobiol. Aging 2006, 27:1289-1297.
29. Kwon M., Chong S., Han S., Kim K. Oxidative stresses elevate the expression of cytochrome c peroxidase in Saccharomyces cerevisiae. Biochim. Biophys. Acta 2003, 1623:1-5.
30. Lillig C.H., Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid. Redox Signal. 2007, 9:25-47.
31. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., et al. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139:27-35.
32. Lohr J.B. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch. Gen. Psychiatry 1991, 48:1097-1106.
33. Lohr J.B., Browning J.A. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol. Bull. 1995, 31:159-165.
34. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 1990, 28:535-539.
35. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 1996, 19:1-17.
36. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry 1998, 43:674-679.
37. McCreadie R.G., MacDonald E., Wiles D., Campbell G., Paterson J.R. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. Br. J. Psychiatry 1995, 167:610-617.
38. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23:315-336.
39. Miyamoto S., Sakamoto T., Soejima H., Shimomura H., Kajiwara I., Kojima S., et al. Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction. Am. Heart J. 2003, 146:465-471.
40. Nagai T., Yamada K., Kim H.C., Kim Y.S., Noda Y., Imura A., et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003, 17:50-52.
41. Nakamura H. Thioredoxin as a key molecule in redox signaling. Antioxid. Redox Signal. 2004, 6:15-17.
42. Nakamura H. Thioredoxin and its related molecules: update 2005. Antioxid. Redox Signal. 2005, 7:823-828.
43. Nakamura H., Nakamura K., Yodoi J. Redox regulation of cellular activation. Annu. Rev. Immunol. 1997, 15:351-369.
44. Nicolle M.M., Gonzalez J., Sugaya K., Baskerville K.A., Bryan D., Lund K., et al. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience 2001, 107:415-431.
45. Owe-Larsson B., Ekdahl K., Edbom T., Osby U., Karlsson H., Lundberg C., et al. Increased plasma levels of thioredoxin-1 in patients with first episode psychosis and long-term schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1117-1121.
46. Palmer B.W., Dawes S.E., Heaton R.K. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol. Rev. 2009, 19:365-384.
47. Radak Z., Kumagai S., Taylor A.W., Naito H., Goto S. Effects of exercise on brain function: role of free radicals. Appl. Physiol. Nutr. Metab. 2007, 32:942-946.
48. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 1998, 20:310-319.
49. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot. Essent. Fat. Acids 1996, 55:33-43.
50. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr. Res. 2003, 62:205-212.
51. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. N. Am. 2003, 26:25-40.
52. Sumida Y., Nakashima T., Yoh T., Nakajima Y., Ishikawa H., Mitsuyoshi H., et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J. Hepatol. 2000, 33:616-622.
53. Takahashi K., Chin K., Nakamura H., Morita S., Sumi K., Oga T., et al. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid. Redox Signal. 2008, 10:715-726.
54. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 2000, 97:137-151.
55. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
56. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res. 2003, 117:85-88.
57. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81:291-300.
58. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Wu G.Y., Cao L.Y., et al. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 2007, 32:2020-2024.
59. Zhang B.H., Tan Y.L., Zhang W.F., Wang Z.R., Yang G.G., Shi C., et al. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a screening test in Chinese: reliability and validity. Chin. Ment. Heal. J. 2009, 28:865-869.
60. Zhang X.Y., Chen da C., Xiu M.H., Wang F., Qi L.Y., Sun H.Q., et al. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr. Res. 2009, 113:151-157.
61. Zhang X.Y., Zhou D.F., Shen Y.C., Zhang P.Y., Zhang W.F., Liang J., et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012, 62:1928-1934.
62. Zhang X.Y., Liang J., Chen, Da C., Xiu M.H., Yang F.D., Kosten T.A., et al. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl) 2012, 222(2):277-284.